CytomX Therapeutics, Inc.-Product Pipeline Review-2016

CytomX Therapeutics, Inc.-Product Pipeline Review-2016

  • Products Id :- GMDHC08066CDB
  • |
  • Pages: 42
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

CytomX Therapeutics, Inc.-Product Pipeline Review-2016


Global Markets Direct's, 'CytomX Therapeutics, Inc.-Product Pipeline Review-2016', provides an overview of the CytomX Therapeutics, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CytomX Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the pipeline therapeutic landscape of CytomX Therapeutics, Inc.

The report provides overview of CytomX Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses CytomX Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features CytomX Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

Evaluate CytomX Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for CytomX Therapeutics, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding CytomX Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

CytomX Therapeutics, Inc. Snapshot 6

CytomX Therapeutics, Inc. Overview 6

Key Information 6

Key Facts 6

CytomX Therapeutics, Inc.-Research and Development Overview 7

Key Therapeutic Areas 7

CytomX Therapeutics, Inc.-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

CytomX Therapeutics, Inc.-Pipeline Products Glance 12

CytomX Therapeutics, Inc.-Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

CytomX Therapeutics, Inc.-Drug Profiles 14

CTX-023 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

CTX-033 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

CTX-1003 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

CX-072 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

CX-2009 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Monoclonal Antibody Conjugate to Target CD-71 for Oncology 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Monoclonal Antibody Conjugate to Target ITGA-3 for Oncology 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Monoclonal Antibody Conjugated to Target CD3 and EGFR for Solid Tumor 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Monoclonal Antibody Conjugates 1 for Oncology 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Monoclonal Antibody Conjugates 2 for Oncology 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Monoclonal Antibody to Antagonize CTLA4 for Oncology 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Cellular Immunotherapy for Oncology 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Monoclonal Antibodies 1 for Oncology 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Monoclonal Antibodies 2 for Oncology 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Monoclonal Antibodies for Oncology 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Monoclonal Antibody Conjugates 3 for Oncology 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Monoclonal Antibody Conjugates for Oncology 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

Monoclonal Antibody to Antagonize Interleukin-6 Receptor for Inflammation 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Monoclonal Antibody to Antagonize PD-1 for Oncology 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

Monoclonal Antibody to Inhibit Glycoprotein-130 for Inflammation 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

CytomX Therapeutics, Inc.-Pipeline Analysis 34

CytomX Therapeutics, Inc.-Pipeline Products by Target 34

CytomX Therapeutics, Inc.-Pipeline Products by Molecule Type 35

CytomX Therapeutics, Inc.-Pipeline Products by Mechanism of Action 36

CytomX Therapeutics, Inc.-Recent Pipeline Updates 37

CytomX Therapeutics, Inc.-Dormant Projects 39

CytomX Therapeutics, Inc.-Locations And Subsidiaries 40

Head Office 40

Appendix 41

Methodology 41

Coverage 41

Secondary Research 41

Primary Research 41

Expert Panel Validation 41

Contact Us 41

Disclaimer 42

List of Figures

CytomX Therapeutics, Inc.-Pipeline by Top 10 Indication, 2016 8

CytomX Therapeutics, Inc.-Pipeline by Stage of Development, 2016 10

CytomX Therapeutics, Inc.-Monotherapy Products in Pipeline, 2016 11

CytomX Therapeutics, Inc.-Pipeline by Top 10 Target, 2016 34

CytomX Therapeutics, Inc.-Pipeline by Molecule Type, 2016 35

CytomX Therapeutics, Inc.-Pipeline Products by Top 10 Mechanism of Action, 2016 36

List of Tables

CytomX Therapeutics, Inc., Key Information 6

CytomX Therapeutics, Inc., Key Facts 6

CytomX Therapeutics, Inc.-Pipeline by Indication, 2016 8

CytomX Therapeutics, Inc.-Pipeline by Stage of Development, 2016 10

CytomX Therapeutics, Inc.-Monotherapy Products in Pipeline, 2016 11

CytomX Therapeutics, Inc.-Preclinical, 2016 12

CytomX Therapeutics, Inc.-Discovery, 2016 13

CytomX Therapeutics, Inc.-Pipeline by Target, 2016 34

CytomX Therapeutics, Inc.-Pipeline by Molecule Type, 2016 35

CytomX Therapeutics, Inc.-Pipeline Products by Mechanism of Action, 2016 36

CytomX Therapeutics, Inc.-Recent Pipeline Updates, 2016 37

CytomX Therapeutics, Inc.-Dormant Developmental Projects,2016 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Current R&D Portfolio of CytomX Therapeutics, Inc.; CytomX Therapeutics, Inc.-Key Therapeutics; CytomX Therapeutics, Inc.-Pipeline Overview and Promising Molecules; CytomX Therapeutics, Inc.-News; CytomX Therapeutics, Inc.-Latest Updates; CytomX Therapeutics, Inc.-Pipeline; CytomX Therapeutics, Inc.-Discontinued/Dormant Projects

select a license
Single User License
USD 1500 INR 110475
Site License
USD 3000 INR 220950
Corporate User License
USD 4500 INR 331425



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]